The Editors of the 2023 ASCO Educational Book
have authorized correction of the following error that published in the paper by Porter, Wen, and Polley, entitled, “Molecular Profiling in Neuro-Oncology: Where We Are, Where We're Heading, and How We Ensure Everyone Can Come Along” (DOI https://doi.org/10.1200/EDBK_389322
In the section “Therapy on the Basis of Molecular Profiling,” the last paragraph has been updated as follows:
“Trials with targeted therapies against these pathways, for example, abemaciclib for glioblastomas with CDKN2A/B loss, buparlisib and paxalisib for tumors with PI3K activation, and numerous agents against EGFR, have been ineffective. Paxalisib, a pi3 kinase inhibitor, did not graduate to stage 2 in GBM Agile, although the patients in that trial were not specifically selected for PI3 kinase pathway activation. Newer agents against EGFR directed at the molecular alterations specific for glioblastomas with good BBB penetration such as BDX1535 and ERAS-801 are in clinical trials.”
The authors apologize for the mistake. This article was corrected on June 30, 2023.